Phase 3 trial data show a synthetic semaglutide injection provides glycemic control comparable to Ozempic in patients with type 2 diabetes.
The entry of Dr Reddy's generic is triggering a price battle among pharmaceutical companies worldwide.
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a ...
Pfizer Inc. today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) ...
Prime Minister Mark Carney will be under pressure to show results from his economic agenda when his government tables an ...
No. 10 / 2026Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved ...
In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1The trial met both weight l ...
Thinking of investing in a grazing muzzle? Here are the best grazing muzzles on the market, plus all you need to know about ...
Learn about the free 12-week citizenship course offered by Catholic Charities of Arkansas, helping immigrants prepare for the ...
Find out how closely you’ve been paying attention to the latest news and other global events by putting your knowledge to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results